Key result
Recombinant human interferon-α1b inhibits SARS-CoV-2 more effectively than interferon-α2b in vitro.
Why the study?
Does recombinant human interferon-α1b inhibit SARS-CoV-2 better than interferon-α2b in vitro?
Does recombinant human interferon-α1b inhibit SARS-CoV-2 better than interferon-α2b in vitro?
Recombinant human interferon-α1b demonstrates significant in vitro antiviral activity against SARS-CoV-2, outperforming interferon-α2b.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of interferon-α1b; leaves open whether in vivo efficacy justifies trials.
• A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID 50 , and immunofluorescence. • A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 cells. • rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2022) studied this question. Recombinant human interferon-α1b inhibited SARS-CoV-2 better than interferon-α2b in vitro, demonstrating significant antiviral effects in Vero and Calu-3 cells.
Synapse has enriched 10 related papers. Consider them for comparative context: